Treatment with antipsychotics is associated with an increased risk of type 2 diabetes mellitus (T2D), and increased levels of inflammatory biomarkers are present in patients with T2D. We previously demonstrated that the glucagon-like peptide-1 receptor agonist liraglutide significantly reduced glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine. This study aims to assess the involvement of cytokines in the therapeutic effects of liraglutide.

Serum concentrations of 10 cytokines (interferon-γ [IFN-γ], tumor necrosis factor-α, interleukin 1β [IL-1β], IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, and IL-13) from fasting prediabetic and normal glucose-tolerant (NGT) patients with schizophrenia-spectrum disorders were measured using multiplexed immunoassays. Prediabetic patients were randomized to 16 weeks of treatment with liraglutide or placebo, and cytokines were measured again at the end of the treatment.

IFN-γ (1.98 vs 1.17 pg/ml, P = .001), IL-4 (0.02 vs 0.01 pg/ml, P < .001), and IL-6 (0.73 vs 0.46 pg/ml, P < .001) were significantly higher in prediabetic (n = 77) vs NGT patients (n = 31). No significant changes in cytokine levels following treatment with liraglutide (n = 37) vs placebo (n = 40) were found.

Prediabetic vs NGT patients with schizophrenia treated with clozapine or olanzapine had increased serum levels of several proinflammatory cytokines, further substantiating the link between inflammation and T2D. Treatment with liraglutide did not affect the investigated cytokines. Further testing of these findings in larger numbers of individuals is needed.

抗精神病药物治疗与 2 型糖尿病 (T2D) 风险增加有关，并且 T2D 患者的炎症生物标志物水平升高。我们之前证明，胰高血糖素样肽-1 受体激动剂利拉鲁肽可显着降低接受氯氮平或奥氮平治疗的前驱糖尿病、超重/肥胖精神分裂症谱系障碍患者的糖代谢紊乱和体重。本研究旨在评估细胞因子在利拉鲁肽治疗效果中的作用。

10 种细胞因子的血清浓度（干扰素-γ [IFN-γ]、肿瘤坏死因子-α、白细胞介素 1β [IL-1β]、IL-2、IL-4、IL-6、IL-8、IL-10、IL -12p70 和 IL-13) 来自患有精神分裂症谱系障碍的禁食前糖尿病和正常葡萄糖耐受 (NGT) 患者，使用多重免疫测定法进行测量。糖尿病前期患者被随机分配到利拉鲁肽或安慰剂治疗 16 周，并在治疗结束时再次测量细胞因子。

IFN-γ (1.98 vs 1.17 pg/ml, P  = .001)、IL-4 (0.02 vs 0.01 pg/ml, P  < .001) 和 IL-6 (0.73 vs 0.46 pg/ml, P  < .001 ) 在糖尿病前期 (n = 77) 与 NGT 患者 (n = 31) 中显着更高。利拉鲁肽（n = 37）与安慰剂（n = 40）治疗后细胞因子水平没有显着变化。

用氯氮平或奥氮平治疗的精神分裂症前驱糖尿病患者与 NGT 患者的血清中几种促炎细胞因子水平升高，进一步证实了炎症与 T2D 之间的联系。利拉鲁肽治疗不影响所研究的细胞因子。需要在大量个体中进一步测试这些发现。